AbbVie 8-K

Summary

Preliminary Q2 2026 acquired IPR&D expense and updated adjusted EPS guidance. AbbVie expects the expense to reduce Q2 GAAP and adjusted diluted EPS by $0.17; results remain subject to closing procedures. Including the expense, the company lowered its Q2 and FY2026 adjusted diluted EPS ranges by $0.17 per share.

Key Figures

• Q2 acquired IPR&D and milestones expense: $291M pretax, with an unfavorable $0.17 impact on both GAAP and adjusted non-GAAP diluted EPS.
• FY2026 acquired IPR&D and milestones expense included in the guidance: $1.035B, including $744M previously announced and the $291M Q2 expense.

Guidance

Investor Takeaways

• Final Q2 results will confirm whether the preliminary expense estimate and its EPS impact hold.
• FY2026 adjusted EPS guidance excludes acquired IPR&D and milestones expense that may occur after Q2, which AbbVie says it cannot reliably forecast.